Positions

Principal Investigator On

Investigator On

  • A Phase 1 / 2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase I Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA) in Children with Relapsed Refractory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia, Study ITCC-054/COG AAML1921  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467,NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML1831A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations”  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1712: A Phase I Trial of Pevonedistat Given in Combination with Fludarabine, Cytarabine, and Azacitidine in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ALTE1631, A Randomized Web-Based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis  awarded by St. Jude Children's Research Hospital
  • Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee
  • PEPCTN1812 - A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • PEPN2112- A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955 -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • WORKLOAD INTENSITY – NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)

    • Education And Training

  • Medical University of South Carolina Medical Cente, Internship
  • Medical University of South Carolina Medical Cente, Residency
  • Children's Hospital of Michigan, Postdoctoral Fellowship
  • Doctor of Medicine, 1998

    • Full Name

  • Ana Xavier